Science · Health
At last, a drug treats the cause of narcolepsy, not just the symptoms
The FDA has approved Orzeyful, the first medicine that restores the signal keeping people with type 1 narcolepsy awake. A target science had been chasing for twenty years.
People with type 1 narcolepsy do not drop off because they are tired: they are missing orexin, the molecule the brain uses to keep you awake. For decades, treatments only covered up one symptom at a time — the daytime sleep, the attacks of muscle weakness. On 5 August 2026, the FDA approved the first one that goes to the root.
First, the basics: narcolepsy is a chronic neurological sleep disorder. Someone who has it cannot control when they fall asleep, and suffers irresistible sleep attacks during the day however much rest they have had. Type 1 adds cataplexy: a sudden loss of muscle tone set off by a strong emotion — a laugh, a fright — that can drop a person to the floor wide awake.
The drug is called oveporexton (sold as Orzeyful, by Takeda) and it does what none of the others did: instead of offsetting the symptoms, it restores the missing signal. Type 1 narcolepsy sets in when the brain loses the neurons that make orexin; without it, the switch that keeps you awake never fully flips. Oveporexton is a “selective orexin receptor 2 agonist”: it takes the place of the absent molecule at the receptor and turns that switch back on.
The wakefulness switch: orexin, type 1 narcolepsy and where the drug acts
From the missing signal to where the new drug acts, in three steps.
1 — Healthy brain
The orexin neurons release the molecule: the wakefulness switch is on.
2 — Type 1 narcolepsy
Those neurons are gone: with no orexin, the switch flips off at the wrong moment (sleep attacks, cataplexy).
3 — With oveporextonOX2R
The drug occupies orexin receptor 2 in place of the absent molecule: the switch comes back on.
Source: own diagram, built from the literature on the orexin system (see the sources).
It is a tablet taken twice a day. The approval rests on two twelve-week phase 3 trials (randomised, double-blind, placebo-controlled) with 273 adults in total. The primary endpoint in both was the Maintenance of Wakefulness Test (MWT), which uses an electroencephalogram to measure how long someone takes to fall asleep across four 40-minute sessions; in one trial it ran alongside the Epworth Sleepiness Scale. At the approved dose, 2 mg twice a day, that latency had risen by 15.9 minutes in one trial and 19.1 in the other by week twelve; on placebo it fell by about a minute. The difference against placebo was 17.2 minutes (95% CI: 13.7 to 20.7) and 20.1 (95% CI: 16.6 to 23.6), with p < .001 in both. The FINI questionnaire, which patients fill in themselves, was a secondary endpoint: in its cognitive function domain, those treated improved by 37.9 and 30.2 points more than placebo on a scale of 0 to 100. Why this matters more than it looks: orexin had been a target since it was discovered some twenty years ago, and until now nobody had turned it into a treatment.
Declared gap. These figures come from the United States public trials registry, where the sponsor deposits them: as of 2 September 2026 there is no peer-reviewed publication of the primary results of these two trials. And the figure Takeda put out when it presented them at a conference — around 70% of patients with no cognitive difficulties, against around 15% on placebo — exists only in its press release, not in the registry. The company is an interested party; it is not used here.
A word on scope, though. This is a United States approval, and approved does not yet mean on the shelf. The DEA has yet to schedule it under the Controlled Substances Act, which Takeda expects within ninety days of approval, and when that comes it will be dispensed through specialty pharmacy, not the pharmacy down the road. China’s NMPA had approved it earlier, on 22 July 2026. Europe not yet: the application to the EMA has not been filed and is expected later in 2026. Type 1 narcolepsy is a rare disease, so this does not change many lives overnight; what changes is the approach, and that opens the door to treating other conditions by going after the cause instead of the symptom.
For the first time, treatment is not chasing the symptoms one by one: it turns the switch that had gone off back on.
For years, narcolepsy patients were given something for the sleep, something for the cataplexy, something to get through the day. With oveporexton, for the first time, a single mechanism sits behind the improvement: the missing signal, restored.
Sources
- FDA — approval announcement for Orzeyful (oveporexton), 5 August 2026 — primary.
- American Academy of Sleep Medicine (AASM) — statement on the approval of Orzeyful for type 1 narcolepsy — independent secondary.
- ClinicalTrials.gov — deposited results of the two phase 3 trials: NCT06470828 (168 participants) and NCT06505031 (105) — primary: the official registry, holding data deposited by the sponsor and not peer-reviewed. Every efficacy figure in this piece comes from here.
- Takeda — press release on the approval, 5 August 2026 — primary, interested source: used only for the mechanism (OX2R agonist), never for the size of the effect.
- AASM (American Academy of Sleep Medicine), NeurologyLive, STAT, FiercePharma — solid secondary.